IRF8 and chronic myelogenous leukemia, BCR-ABL1 positive: As Fas resistance contributes to persistence and expansion of CML leukemic stem cells (LSCs), it led to imatinib resistance in BCR − ABL + GMPs through the reduction of IRF8 expression and increased FAP1 expression (61).